CDA | Evidence Driven
CDA | Evidence Driven

pembrolizumab

Details

Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
Non-small cell lung cancer (NSCLC)
Manufacturer:
Merck Canada
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0369-000
Call for patient/clinician input closed:
Tumour Type:
Lung
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​ ​Keytruda as monotherapy for the adjuvant treatment of adult patients with Stage IB (T2a ≥ 4 cm), II, or IIIA NSCLC, and with PD-L1 tumor proportion score (TPS) < 50% who have undergone complete resection and platinum-based chemotherapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Keytruda as monotherapy is indicated for the adjuvant treatment of adult patients with Stage IB (T2a ≥ 4 cm), II, or IIIA NSCLC who have undergone complete resection and platinum-based chemotherapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : June 3, 2024